ANAPC13

Summary

ANAPC13 (anaphase promoting complex subunit 13, HGNC:24540) is a protein-coding gene on chromosome 3q22.2, encoding Anaphase-promoting complex subunit 13 (Q9BS18). Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. It is a selective cancer dependency (DepMap: 65.5% of cell lines).

This gene encodes a component of the anaphase promoting complex, a large ubiquitin-protein ligase that controls cell cycle progression by regulating the degradation of cell cycle regulators such as B-type cyclins. The encoded protein is evolutionarily conserved and is required for the integrity and ubiquitin ligase activity of the anaphase promoting complex. Pseudogenes and splice variants have been found for this gene; however, the biological validity of some of the splice variants has not been determined.

Source: NCBI Gene 25847 — RefSeq curated summary.

At a glance

• GWAS associations: 24
• Clinical variants (ClinVar): 17 total — 2 pathogenic
• Cancer dependency (DepMap): dependent in 65.5% of screened cell lines
• MANE Select transcript: NM_015391

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24540
Approved symbol	ANAPC13
Name	anaphase promoting complex subunit 13
Location	3q22.2
Locus type	gene with protein product
Status	Approved
Aliases	SWM1, APC13, DKFZP566D193
Ensembl gene	ENSG00000129055
Ensembl biotype	protein_coding
OMIM	614484
Entrez	25847

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 18 protein_coding, 2 retained_intron

ENST00000354910, ENST00000503439, ENST00000508755, ENST00000510994, ENST00000511751, ENST00000514612, ENST00000891857, ENST00000891858, ENST00000891859, ENST00000891860, ENST00000891861, ENST00000891862, ENST00000891863, ENST00000891864, ENST00000891865, ENST00000924686, ENST00000924687, ENST00000924688, ENST00000961476, ENST00000961477

RefSeq mRNA: 3 — MANE Select: NM_015391 NM_001242374, NM_001242375, NM_015391

CCDS: CCDS3085

Canonical transcript exons

ENST00000354910 — 3 exons

Exon	Start	End
ENSE00000885901	134482806	134482931
ENSE00001413445	134485952	134485985
ENSE00002078678	134477706	134478715

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 98.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.0085 / max 775.5929, expressed in 1813 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
44707	26.5400	1806
44706	4.8023	1632
44704	2.1221	1083
44705	0.3713	151
44703	0.1728	60

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	98.72	gold quality
parotid gland	UBERON:0001831	98.52	gold quality
pigmented layer of retina	UBERON:0001782	98.50	gold quality
corpus epididymis	UBERON:0004359	98.43	gold quality
palpebral conjunctiva	UBERON:0001812	98.10	gold quality
kidney epithelium	UBERON:0004819	98.05	gold quality
heart right ventricle	UBERON:0002080	98.01	gold quality
renal glomerulus	UBERON:0000074	97.98	gold quality
caput epididymis	UBERON:0004358	97.96	gold quality
metanephric glomerulus	UBERON:0004736	97.84	gold quality
cauda epididymis	UBERON:0004360	97.76	gold quality
renal medulla	UBERON:0000362	97.72	gold quality
myocardium	UBERON:0002349	97.69	gold quality
left ventricle myocardium	UBERON:0006566	97.39	gold quality
germinal epithelium of ovary	UBERON:0001304	97.38	gold quality
metanephros	UBERON:0000081	97.37	gold quality
islet of Langerhans	UBERON:0000006	97.28	gold quality
hypothalamus	UBERON:0001898	97.24	gold quality
upper leg skin	UBERON:0004262	97.16	gold quality
choroid plexus epithelium	UBERON:0003911	97.15	gold quality
visceral pleura	UBERON:0002401	97.10	gold quality
cortex of kidney	UBERON:0001225	97.09	gold quality
parietal pleura	UBERON:0002400	97.09	gold quality
pleura	UBERON:0000977	97.07	gold quality
bronchial epithelial cell	CL:0002328	97.06	gold quality
skin of hip	UBERON:0001554	97.03	gold quality
adult mammalian kidney	UBERON:0000082	97.00	gold quality
kidney	UBERON:0002113	96.94	gold quality
epithelium of bronchus	UBERON:0002031	96.87	gold quality
middle temporal gyrus	UBERON:0002771	96.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting ANAPC13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-12132	99.47	68.90	1341
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4797-5P	99.39	68.01	1354
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 65.5% of screened cell lines.

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	anapc13	ENSDARG00000078435
mus_musculus	Anapc13	ENSMUSG00000035048
rattus_norvegicus	Anapc13	ENSRNOG00000008459

Protein

Protein identifiers

Anaphase-promoting complex subunit 13 — Q9BS18 (reviewed: Q9BS18)

Alternative names: Cyclosome subunit 13

All UniProt accessions (2): Q9BS18, A8K3Z6

UniProt curated annotations — full annotation on UniProt →

Function. Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of ‘Lys-11’-linked polyubiquitin chains and, to a lower extent, the formation of ‘Lys-48’- and ‘Lys-63’-linked polyubiquitin chains. The APC/C complex catalyzes assembly of branched ‘Lys-11’-/‘Lys-48’-linked branched ubiquitin chains on target proteins.

Subunit / interactions. The mammalian APC/C is composed at least of 14 distinct subunits ANAPC1, ANAPC2, CDC27/APC3, ANAPC4, ANAPC5, CDC16/APC6, ANAPC7, CDC23/APC8, ANAPC10, ANAPC11, CDC26/APC12, ANAPC13, ANAPC15 and ANAPC16 that assemble into a complex of at least 19 chains with a combined molecular mass of around 1.2 MDa; APC/C interacts with FZR1 and FBXO5.

Subcellular location. Nucleus.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the APC13 family.

RefSeq proteins (3): NP_001229303, NP_001229304, NP_056206* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008401	Apc13	Family

Pfam: PF05839

UniProt features (9 total): helix 4, sequence conflict 2, chain 1, region of interest 1, strand 1

Structure

Experimental structures (PDB)

20 structures.

PDB	Method	Resolution (Å)
9GAW	ELECTRON MICROSCOPY	2.9
6Q6G	ELECTRON MICROSCOPY	3.2
6Q6H	ELECTRON MICROSCOPY	3.2
8PKP	ELECTRON MICROSCOPY	3.2
5G05	ELECTRON MICROSCOPY	3.4
8TAU	ELECTRON MICROSCOPY	3.5
4UI9	ELECTRON MICROSCOPY	3.6
6TNT	ELECTRON MICROSCOPY	3.78
6TLJ	ELECTRON MICROSCOPY	3.8
5G04	ELECTRON MICROSCOPY	3.9
6TM5	ELECTRON MICROSCOPY	3.9
9N9R	ELECTRON MICROSCOPY	3.9
9N9S	ELECTRON MICROSCOPY	3.9
8TAR	ELECTRON MICROSCOPY	4
5LCW	ELECTRON MICROSCOPY	4.2
5A31	ELECTRON MICROSCOPY	4.3
5KHU	ELECTRON MICROSCOPY	4.8
5KHR	ELECTRON MICROSCOPY	6.1
5L9T	ELECTRON MICROSCOPY	6.4
5L9U	ELECTRON MICROSCOPY	6.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BS18-F1	74.06	0.13

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 169 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_ANAPHASE_PROMOTING_COMPLEX_DEPENDENT_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_MEIOTIC_CELL_CYCLE, GOBP_PROTEIN_K11_LINKED_UBIQUITINATION, GOBP_REGULATION_OF_CELL_CYCLE, MORF_PPP6C, GOBP_REGULATION_OF_REPRODUCTIVE_PROCESS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, GOBP_MITOTIC_CELL_CYCLE

GO Biological Process (8): regulation of mitotic cell cycle (GO:0007346), anaphase-promoting complex-dependent catabolic process (GO:0031145), cell division (GO:0051301), regulation of meiotic cell cycle (GO:0051445), protein K48-linked ubiquitination (GO:0070936), protein K11-linked ubiquitination (GO:0070979), protein branched polyubiquitination (GO:0141198), protein ubiquitination (GO:0016567)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): anaphase-promoting complex (GO:0005680), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein polyubiquitination	3
regulation of cell cycle	2
mitotic cell cycle	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
cellular process	1
meiotic cell cycle	1
regulation of reproductive process	1
protein modification by small protein conjugation	1
binding	1
nuclear ubiquitin ligase complex	1
cullin-RING ubiquitin ligase complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

964 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANAPC13	CDC26	Q8NHZ8	965
ANAPC13	ANAPC10	Q9UM13	963
ANAPC13	ANAPC16	Q96DE5	944
ANAPC13	CDC23	Q9UJX2	925
ANAPC13	ANAPC11	Q9NYG5	877
ANAPC13	ANAPC15	P60006	867
ANAPC13	ANAPC5	Q9UJX4	855
ANAPC13	CDC16	Q13042	843
ANAPC13	CDC27	P30260	794
ANAPC13	CDC20	Q12834	671
ANAPC13	OR2B3	O76000	507
ANAPC13	SLC35F4	A4IF30	474
ANAPC13	CDK2	P24941	468
ANAPC13	ANAPC4	Q9UJX5	457
ANAPC13	FZR1	Q9UM11	452

IntAct

54 interactions, top by confidence:

A	B	Type	Score
CDC20	BUB1B	psi-mi:“MI:0914”(association)	0.980
ANAPC2	CDC27	psi-mi:“MI:0915”(physical association)	0.910
ANAPC13	CDC23	psi-mi:“MI:0915”(physical association)	0.880
ANAPC4	CDC27	psi-mi:“MI:0914”(association)	0.860
ANAPC5	CDC27	psi-mi:“MI:0914”(association)	0.810
CDC16	BUB1B	psi-mi:“MI:0914”(association)	0.790
CDC23	BUB1B	psi-mi:“MI:0914”(association)	0.790
ANAPC16	BUB1B	psi-mi:“MI:0914”(association)	0.730
ANAPC2	BUB1B	psi-mi:“MI:0914”(association)	0.730
ANAPC13	CDC27	psi-mi:“MI:0914”(association)	0.640
CDC26	BUB1B	psi-mi:“MI:0914”(association)	0.640
C16orf87	CDC27	psi-mi:“MI:0914”(association)	0.640
Cdc20	BUB1	psi-mi:“MI:0914”(association)	0.560
Cdc20	BUB1	psi-mi:“MI:0915”(physical association)	0.560
Cdc23	BUB1B	psi-mi:“MI:0915”(physical association)	0.560
Cdc16	BUB1B	psi-mi:“MI:0915”(physical association)	0.560
Cdc26	BUB1B	psi-mi:“MI:0915”(physical association)	0.560
ANAPC13	WFS1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (133): ANAPC13 (Two-hybrid), ANAPC13 (Affinity Capture-RNA), ANAPC13 (Affinity Capture-RNA), ANAPC13 (Co-purification), ANAPC13 (Affinity Capture-Western), ANAPC13 (Co-fractionation), TAF4 (Co-fractionation), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS), ANAPC13 (Affinity Capture-MS)

ESM2 similar proteins: A0A023IWK5, A2BT05, A2BYF5, A2C4H7, A5PJU8, A8W7N1, K4JY29, O64242, P02677, P03715, P04564, P06885, P07543, P09692, P0C2K6, P0DJH2, P0DTH7, P11967, P31182, P33713, P43511, P52820, P68116, P68117, P68249, P80504, P80529, P83767, P85087, P85112, P85211, P85509, P85512, P85800, P86043, P86929, Q2NKV2, Q32PD7, Q3U898, Q46J74

Diamond homologs: Q28IW8, Q2NKV2, Q5RBV4, Q8R034, Q9BS18

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ANAPC13	“form complex”	APC-c	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	13	434.1×	2e-33
Inactivation of APC/C via direct inhibition of the APC/C complex	13	355.2×	7e-32
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase	11	300.5×	3e-26
APC-Cdc20 mediated degradation of Nek2A	13	289.4×	1e-30
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	13	289.4×	1e-30
Phosphorylation of the APC/C	10	286.2×	2e-23
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	13	279.1×	2e-30
Aberrant regulation of mitotic exit in cancer due to RB1 defects	10	273.2×	3e-23

GO biological processes:

GO term	Partners	Fold	FDR
regulation of meiotic cell cycle	11	421.3×	2e-26
protein branched polyubiquitination	10	421.3×	2e-24
anaphase-promoting complex-dependent catabolic process	11	386.2×	3e-26
protein K11-linked ubiquitination	10	195.9×	1e-20
mitotic spindle assembly checkpoint signaling	5	140.4×	2e-09
regulation of mitotic cell cycle	11	132.4×	1e-20
protein K48-linked ubiquitination	10	84.3×	9e-17
cell division	15	34.6×	2e-20

Disease & clinical

Clinical variants and AI predictions

ClinVar

17 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	10
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1708468	GRCh37/hg19 3q22.2(chr3:133998370-134678040)x1	Pathogenic
4279117	GRCh37/hg19 3q22.2(chr3:134113279-134337513)x1	Pathogenic

SpliceAI

630 predictions. Top by Δscore:

Variant	Effect	Δscore
3:134478712:CATT:C	acceptor_gain	1.0000
3:134478714:TT:T	acceptor_gain	1.0000
3:134482822:T:TA	donor_gain	1.0000
3:134485100:T:TA	donor_gain	1.0000
3:134478711:TCATT:T	acceptor_gain	0.9900
3:134478712:CATTC:C	acceptor_gain	0.9900
3:134478714:TTCTG:T	acceptor_loss	0.9900
3:134478715:TCTGA:T	acceptor_loss	0.9900
3:134478716:C:CC	acceptor_gain	0.9900
3:134478717:T:A	acceptor_loss	0.9900
3:134482801:CCT:C	donor_loss	0.9900
3:134482802:CTA:C	donor_loss	0.9900
3:134482804:A:AC	donor_gain	0.9900
3:134482804:ACC:A	donor_loss	0.9900
3:134482805:C:CC	donor_gain	0.9900
3:134482927:CAAAT:C	acceptor_gain	0.9900
3:134482928:AAATC:A	acceptor_loss	0.9900
3:134482930:ATC:A	acceptor_loss	0.9900
3:134482932:C:CC	acceptor_gain	0.9900
3:134482933:T:G	acceptor_loss	0.9900
3:134478713:ATT:A	acceptor_gain	0.9700
3:134482928:AAAT:A	acceptor_gain	0.9600
3:134482934:G:C	acceptor_loss	0.9600
3:134485072:C:CA	donor_gain	0.9600
3:134485659:T:A	donor_gain	0.9600
3:134485731:T:TA	donor_gain	0.9600
3:134478724:G:C	acceptor_gain	0.9500
3:134478718:G:C	acceptor_loss	0.9400
3:134482805:CCA:C	donor_gain	0.9400
3:134482929:AAT:A	acceptor_gain	0.9400

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000813621 (3:134483449 AG>A), RS1000849571 (3:134478736 T>A), RS1001369834 (3:134485301 A>G), RS1002333677 (3:134482892 C>A), RS1002660373 (3:134485998 C>A,T), RS1002707571 (3:134485844 C>A), RS1003526390 (3:134486225 G>A,C,T), RS1003606310 (3:134481395 C>T), RS1003765302 (3:134486391 CG>C), RS1003861050 (3:134482512 A>G), RS1003939031 (3:134481722 T>G), RS1004237989 (3:134486681 T>A,G), RS1004369669 (3:134480987 T>G), RS1004381127 (3:134480624 T>C), RS1004696123 (3:134486473 A>G)

Disease associations

OMIM: gene MIM:614484 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST000174_11	Height	7.000000e-08
GCST004063_33	Waist circumference adjusted for body mass index	8.000000e-07
GCST004063_38	Waist circumference adjusted for body mass index	2.000000e-11
GCST004063_42	Waist circumference adjusted for body mass index	1.000000e-06
GCST004407_3	Neurocognitive impairment in HIV-1 infection (dichotomous)	2.000000e-06
GCST004500_102	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	1.000000e-12
GCST004500_13	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	2.000000e-08
GCST004500_51	Waist circumference adjusted for BMI (adjusted for smoking behaviour)	6.000000e-07
GCST004501_26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	8.000000e-07
GCST004501_7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	7.000000e-13
GCST004501_8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	4.000000e-07
GCST004504_4	Waist circumference adjusted for BMI in non-smokers	9.000000e-07
GCST004504_5	Waist circumference adjusted for BMI in non-smokers	2.000000e-12
GCST004504_6	Waist circumference adjusted for BMI in non-smokers	2.000000e-07
GCST004562_177	Waist circumference adjusted for body mass index	9.000000e-09
GCST004562_75	Waist circumference adjusted for body mass index	4.000000e-06
GCST004562_91	Waist circumference adjusted for body mass index	1.000000e-09
GCST004563_227	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	2.000000e-08
GCST004563_68	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	2.000000e-09
GCST004563_82	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	5.000000e-06
GCST004564_123	Waist circumference adjusted for BMI in active individuals	4.000000e-09
GCST004564_124	Waist circumference adjusted for BMI in active individuals	2.000000e-06
GCST004564_125	Waist circumference adjusted for BMI in active individuals	4.000000e-10
GCST008839_555	Height	9.000000e-19

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference
EFO:0007998	cognitive impairment measurement
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
aristolochic acid I	increases expression	1
dicrotophos	decreases expression	1
beauvericin	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
trichostatin A	affects expression	1
sodium arsenite	decreases expression	1
1-aminomethylphosphonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
enniatins	affects cotreatment, decreases expression	1
Glyphosate	decreases expression	1
Chelating Agents	affects binding, decreases expression	1
Copper	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Ozone	affects expression, increases abundance	1
Valproic Acid	affects expression	1
Aflatoxin M1	decreases expression	1
Monocrotaline	increases expression, increases metabolic processing	1
Okadaic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.